Feline Hyperaldosteronism: Diagnosis and Management

Feline hyperaldosteronism, also known as primary hyperaldosteronism or Conn's syndrome in cats, is an endocrine disorder characterized by excessive aldosterone production from the adrenal glands, leading to systemic hypertension and hypokalemia. This article provides veterinary clinicians with evidence-based guidance on pathophysiology, clinical recognition, diagnostic testing including the aldosterone:renin ratio and adrenal imaging, and treatment options including surgical adrenalectomy and medical management with spironolactone. The content is grounded in peer-reviewed literature and official veterinary guidelines, with clear separation of observation, first-response actions, and escalation criteria for specialist referral.

At a Glance

Pathophysiology and Epidemiology

Primary hyperaldosteronism in cats results from autonomous aldosterone secretion by the adrenal cortex, independent of the renin-angiotensin system. The condition is classified as either unilateral aldosterone-producing adenoma (aldosteronoma) or bilateral adrenal hyperplasia. Adrenal carcinoma is a less common cause. The excessive aldosterone promotes renal sodium retention and potassium excretion, leading to volume expansion, hypertension, and hypokalemia.

The disorder is considered underdiagnosed in feline practice, as many affected cats present with nonspecific signs or are identified during routine blood pressure screening. The 2020 review in The Veterinary Clinics of North America. Small Animal Practice highlights that primary hyperaldosteronism is an underdiagnosed disorder in cats, emphasizing the need for heightened clinical suspicion in hypertensive or hypokalemic patients. The 2010 review in The Veterinary Clinics of North America. Small Animal Practice provides historical context on the recognition of feline primary hyperaldosteronism as a distinct clinical entity. The 2005 review in The Veterinary Clinics of North America. Small Animal Practice discusses the spectrum of feline endocrinopathies and their overlapping clinical presentations, reinforcing the need for systematic evaluation in cats with compatible signs.

Clinical Signs and Physical Examination Findings

Clinical manifestations of feline hyperaldosteronism are primarily attributable to hypertension and hypokalemia. Common presenting signs include:

• Ocular signs: Acute blindness, retinal detachment, or intraocular hemorrhage due to severe hypertension
• Neuromuscular signs: Cervical ventroflexion, weakness, lethargy, or episodic collapse from hypokalemia
• Cardiovascular signs: Gallop rhythm, murmur, or signs of congestive heart failure secondary to hypertension
• Renal signs: Polyuria and polydipsia, often due to hypokalemic nephropathy

Physical examination should include careful fundic examination for retinal changes, assessment of cervical muscle tone, and blood pressure measurement. The Merck Veterinary Manual provides general guidance on feline hypertension evaluation, noting that systolic blood pressure above 160 mmHg warrants investigation for underlying causes including hyperaldosteronism.

Diagnostic Approach

Initial Laboratory Assessment

The diagnostic workup begins with routine biochemistry and electrolyte measurement. Hypokalemia is a hallmark finding, though not all affected cats are hypokalemic at presentation. Serum potassium concentrations below 3.5 mEq/L should raise suspicion. Concurrent hypertension, particularly systolic blood pressure above 160 mmHg, strengthens the index of suspicion.

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines provide a framework for endocrine disease diagnosis, emphasizing the importance of systematic evaluation in cats with compatible clinical signs. These guidelines support the use of standardized diagnostic protocols to improve detection rates for conditions such as hyperaldosteronism.

Aldosterone:Renin Ratio

The aldosterone:renin ratio (ARR) is the recommended screening test for primary hyperaldosteronism. This test requires measurement of plasma aldosterone concentration and plasma renin activity. In primary hyperaldosteronism, aldosterone is elevated while renin is suppressed, resulting in a high ARR.

Sample handling is critical: blood should be collected into chilled EDTA tubes, centrifuged promptly, and plasma frozen until assay. The test is best performed in a reference laboratory with validated feline assays. The 2020 review in The Veterinary Clinics of North America. Small Animal Practice discusses the utility of ARR in diagnosing this underrecognized condition.

Confirmatory Testing

When ARR is equivocal or clinical suspicion remains high despite normal ARR, additional testing may be indicated. The fludrocortisone suppression test or saline infusion test can help confirm autonomous aldosterone secretion, though these are less commonly performed in clinical practice. The 2010 review in The Veterinary Clinics of North America. Small Animal Practice provides historical context on diagnostic approaches for feline primary hyperaldosteronism.

Adrenal Imaging

Abdominal ultrasound is the initial imaging modality to identify adrenal masses or bilateral hyperplasia. Unilateral aldosteronomas typically appear as well-defined, hypoechoic nodules within the adrenal gland. Bilateral hyperplasia may show diffuse enlargement without discrete nodules. Computed tomography (CT) provides superior anatomic detail and is recommended for surgical planning when an adrenal mass is identified.

The 2007 review in Clinical Techniques in Small Animal Practice discusses feline adrenal disorders and imaging characteristics, providing guidance on interpretation of adrenal imaging findings.

Differential Diagnoses

Conditions that mimic feline hyperaldosteronism include:

• Chronic kidney disease: Can cause hypertension and hypokalemia, but renin activity is typically normal or elevated
• Hyperthyroidism: Hypertension is common, but hypokalemia is unusual
• Diabetes mellitus: May cause hypokalemia from polyuria, but hypertension is less prominent
• Hypokalemic polymyopathy: Can occur in cats with low potassium intake or gastrointestinal losses, but hypertension is absent

The 2005 review in The Veterinary Clinics of North America. Small Animal Practice provides broader context on feline endocrinopathies and their overlapping presentations, helping clinicians differentiate hyperaldosteronism from other endocrine disorders.

Treatment Options

Surgical Management

Unilateral adrenalectomy is the treatment of choice for cats with a solitary aldosteronoma and no evidence of metastasis. Surgical removal of the affected adrenal gland can resolve hypertension and hypokalemia in many cases. Preoperative stabilization is essential: blood pressure should be controlled with antihypertensives, and potassium levels normalized with supplementation.

The procedure carries risks including hemorrhage, pancreatitis, and hypoadrenocorticism if the contralateral gland is atrophied. Postoperative monitoring includes blood pressure, electrolytes, and cortisol levels. The 2001 review in The Veterinary Clinics of North America. Small Animal Practice discusses surgical considerations for feline endocrine disorders, including perioperative management of adrenal disease.

Medical Management

For cats with bilateral hyperplasia, metastatic disease, or those that are poor surgical candidates, medical management is indicated. Spironolactone is the primary medical therapy, acting as a mineralocorticoid receptor antagonist. It directly counteracts aldosterone effects, promoting potassium retention and sodium excretion.

Dosing must be individualized based on response, and monitoring for side effects such as gastrointestinal upset or hyperkalemia is necessary. Antihypertensive therapy, typically with amlodipine, is often required concurrently. Potassium supplementation may be needed initially but should be tapered as spironolactone takes effect.

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines provide general monitoring recommendations for endocrine disorders, supporting the use of structured follow-up protocols in cats receiving medical therapy for hyperaldosteronism.

Monitoring and Long-Term Care

Regular monitoring of blood pressure, serum potassium, and renal function is essential. The frequency of rechecks depends on disease severity and treatment response. Cats on spironolactone should have electrolytes measured 1-2 weeks after initiation and then every 3-6 months. Blood pressure should be reassessed at each visit. The goal is systolic blood pressure below 160 mmHg and normokalemia.

Practical Implementation Steps

Step 1: Identify Suspect Cases

Screen cats with hypertension (systolic >160 mmHg), hypokalemia (<3.5 mEq/L), or compatible clinical signs such as cervical ventroflexion or acute blindness. Measure blood pressure using Doppler or oscillometric methods following standard protocols. Record all measurements in the medical record.

Step 2: Perform Initial Laboratory Workup

Collect blood for complete blood count, biochemistry panel including electrolytes, and thyroid testing to rule out hyperthyroidism. If hypokalemia and hypertension are confirmed, proceed to aldosterone and renin testing.

Step 3: Collect Samples for Aldosterone:Renin Ratio

Use chilled EDTA tubes, centrifuge within 30 minutes, and freeze plasma. Ship on dry ice to a reference laboratory with validated feline assays. Record sample collection time, handling details, and laboratory results.

Step 4: Perform Adrenal Imaging

Schedule abdominal ultrasound to evaluate adrenal gland size and architecture. If a unilateral mass is identified, consider CT for surgical planning. Record imaging findings including adrenal dimensions, echogenicity, and presence of metastases.

Step 5: Initiate Treatment

For unilateral aldosteronoma without metastases, refer for surgical adrenalectomy. For bilateral hyperplasia or non-surgical candidates, start spironolactone and antihypertensives. Document treatment plan, drug doses, and monitoring schedule.

Step 6: Monitor Response

Recheck blood pressure and electrolytes 1-2 weeks after treatment initiation, then every 3-6 months. Adjust therapy based on response. Record all follow-up data and any adverse effects.

Records and Measurements

Maintain detailed records for each suspected or confirmed case:

• Blood pressure measurements (date, time, method, systolic/diastolic values)
• Serum potassium and sodium concentrations
• Aldosterone and renin activity results with ARR calculation
• Imaging reports (adrenal size, laterality, characteristics)
• Treatment history (drug, dose, frequency, start date)
• Monitoring data (blood pressure, electrolytes, renal function)
• Surgical reports if applicable
• Outcome data (resolution of signs, complications, survival)

These records support clinical decision-making, facilitate referral communication, and contribute to the evidence base for feline hyperaldosteronism management.

Common Failure Patterns

Failure to Screen

Many clinicians do not routinely measure blood pressure in cats, leading to missed diagnoses. Hypertension is often asymptomatic until advanced, and hypokalemia may be intermittent. The 2020 review in The Veterinary Clinics of North America. Small Animal Practice emphasizes that primary hyperaldosteronism is underdiagnosed, suggesting that systematic screening in at-risk populations would improve detection rates.

Inadequate Sample Handling

Improper collection or handling of samples for aldosterone and renin testing can yield false results. Delayed centrifugation, use of incorrect tubes, or improper storage can degrade these labile hormones. Strict adherence to laboratory protocols is essential.

Misinterpretation of Imaging

Small adrenal nodules may be missed on ultrasound, and bilateral hyperplasia can be subtle. CT provides better sensitivity for detecting adrenal abnormalities. If clinical suspicion remains high despite negative imaging, referral to a specialist center for advanced imaging should be considered.

Incomplete Preoperative Stabilization

Surgery on a cat with uncontrolled hypertension or severe hypokalemia carries increased anesthetic risk. Preoperative optimization of blood pressure and electrolytes is mandatory. The 2007 review in Clinical Techniques in Small Animal Practice discusses perioperative considerations for feline adrenal disorders.

Inadequate Long-Term Monitoring

Cats on medical therapy require lifelong monitoring. Spironolactone can cause hyperkalemia, especially in cats with concurrent renal disease. Antihypertensive doses may need adjustment over time. Regular rechecks are necessary to maintain control and detect complications.

Limitations and Considerations

Diagnostic Limitations

The aldosterone:renin ratio is not 100% sensitive or specific. False positives can occur with certain medications (e.g., diuretics, ACE inhibitors) and false negatives in early disease. Confirmatory testing may be needed in equivocal cases. The 2010 review in The Veterinary Clinics of North America. Small Animal Practice discusses diagnostic challenges in feline primary hyperaldosteronism.

Treatment Limitations

Spironolactone is not universally effective, and some cats require additional antihypertensives. Surgical adrenalectomy is curative for unilateral disease but carries operative risks. Adrenal carcinoma may recur or metastasize. The 2005 review in The Veterinary Clinics of North America. Small Animal Practice provides context on treatment outcomes for feline endocrinopathies.

Regulatory and Safety Context

Spironolactone is not approved for use in cats by regulatory agencies in many countries, its use is extra-label. Clinicians should obtain informed consent and document the rationale for its use. The World Organisation for Animal Health provides general guidance on responsible antimicrobial and therapeutic use, though specific feline endocrinology guidelines are not within its scope.

Professional Escalation Criteria

Refer to a veterinary internal medicine specialist or veterinary teaching hospital in the following situations:

• Diagnostic uncertainty after initial workup (equivocal ARR, negative imaging with high suspicion)
• Complex surgical cases (large adrenal mass, suspected carcinoma, bilateral disease)
• Poor response to medical therapy (persistent hypertension or hypokalemia despite optimized treatment)
• Complications of therapy (severe hyperkalemia, renal deterioration, adverse drug reactions)
• Need for advanced imaging (CT, MRI) or specialized testing (adrenal vein sampling)

The American College of Veterinary Internal Medicine (ACVIM) provides resources for locating board-certified specialists.

Practical Decision Framework for Feline Hyperaldosteronism Management

A structured decision framework helps clinicians navigate the diagnostic and therapeutic steps for feline hyperaldosteronism with clarity and consistency. This section provides a stepwise approach to case management, from initial suspicion through long-term monitoring, with specific criteria for treatment selection and escalation. The framework is designed to be used alongside clinical judgment and is grounded in the diagnostic principles outlined in the 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines and the 2020 review in The Veterinary Clinics of North America. Small Animal Practice.

Step 1: Case Identification and Risk Stratification

The first decision point is identifying cats that warrant diagnostic evaluation for hyperaldosteronism. The following criteria should trigger a full workup:

• Systolic blood pressure consistently above 160 mmHg measured by Doppler or oscillometric methods following standard protocols
• Serum potassium concentration below 3.5 mEq/L on at least one occasion
• Compatible clinical signs including cervical ventroflexion, episodic weakness, acute blindness, or retinal detachment
• Unexplained polyuria and polydipsia with normal renal function

Cats meeting one or more of these criteria should be classified as high priority for diagnostic testing. Cats with hypertension alone, without hypokalemia, should still be considered for screening if other causes of hypertension (hyperthyroidism, chronic kidney disease, diabetes mellitus) have been excluded. The Merck Veterinary Manual provides general guidance on feline hypertension evaluation, noting that systolic blood pressure above 160 mmHg warrants investigation for underlying causes.

Step 2: Initial Laboratory Assessment and Sample Collection

Once a suspect case is identified, the following laboratory tests should be performed:

• Complete blood count
• Biochemistry panel including electrolytes, creatinine, blood urea nitrogen, and glucose
• Total thyroxine to rule out hyperthyroidism
• Urinalysis with specific gravity

If hypokalemia and hypertension are confirmed, proceed to collect samples for aldosterone and renin testing. Sample handling is critical for accurate results. Use the following protocol:

• Collect blood into chilled EDTA tubes
• Centrifuge within 30 minutes of collection
• Separate plasma and freeze immediately
• Ship on dry ice to a reference laboratory with validated feline assays
• Record collection time, handling details, and laboratory results in the medical record

The 2020 review in The Veterinary Clinics of North America. Small Animal Practice emphasizes that primary hyperaldosteronism is underdiagnosed, and proper sample handling is essential to avoid false negatives.

Step 3: Interpretation of Aldosterone:Renin Ratio

The aldosterone:renin ratio (ARR) is the recommended screening test. Interpretation requires understanding of the expected patterns:

• Primary hyperaldosteronism: Elevated aldosterone with suppressed renin, resulting in a high ARR
• Secondary hyperaldosteronism: Elevated aldosterone with elevated renin, resulting in a normal or low ARR
• Normal: Aldosterone and renin within reference ranges

Reference ranges vary by laboratory, and clinicians should use the reference intervals provided by their specific laboratory. If the ARR is equivocal or clinical suspicion remains high despite a normal ARR, consider confirmatory testing or referral to a veterinary internal medicine specialist. The 2010 review in The Veterinary Clinics of North America. Small Animal Practice provides historical context on diagnostic approaches for feline primary hyperaldosteronism.

Step 4: Adrenal Imaging and Lesion Characterization

Abdominal ultrasound is the initial imaging modality. Record the following findings:

• Adrenal gland dimensions (normal feline adrenal glands are approximately 10-15 mm in length)
• Presence of discrete nodules or masses
• Echogenicity and shape of the adrenal glands
• Evidence of invasion into surrounding tissues
• Presence of metastases in the liver, spleen, or regional lymph nodes

If a unilateral mass is identified, computed tomography (CT) is recommended for surgical planning. CT provides superior anatomic detail and can detect smaller lesions missed on ultrasound. The 2007 review in Clinical Techniques in Small Animal Practice discusses feline adrenal disorders and imaging characteristics, providing guidance on interpretation of adrenal imaging findings.

Step 5: Treatment Selection Based on Lesion Type

The treatment decision is based on the type of adrenal pathology identified:

Unilateral Aldosteronoma (Adenoma or Carcinoma)

• Surgical adrenalectomy is the treatment of choice if no metastases are present
• Preoperative stabilization is essential: control blood pressure with amlodipine and normalize potassium with supplementation
• Refer to a veterinary surgical specialist or teaching hospital for the procedure
• Postoperative monitoring includes blood pressure, electrolytes, and cortisol levels

Bilateral Adrenal Hyperplasia

• Medical management with spironolactone is indicated
• Antihypertensive therapy with amlodipine is often required concurrently
• Potassium supplementation may be needed initially but should be tapered as spironolactone takes effect
• Lifelong monitoring is necessary

Non-Surgical Candidate (Regardless of Lesion Type)

• Cats with metastatic disease, severe concurrent illness, or owner preference against surgery
• Medical management as above
• Regular monitoring for disease progression

The 2001 review in The Veterinary Clinics of North America. Small Animal Practice discusses surgical considerations for feline endocrine disorders, including perioperative management of adrenal disease.

Step 6: Medical Therapy Initiation and Dose Adjustment

For cats receiving spironolactone, use the following approach:

• Starting dose: 1-2 mg/kg orally every 12 hours
• Monitor electrolytes 1-2 weeks after initiation
• Adjust dose based on potassium response: increase if hypokalemia persists, decrease if hyperkalemia develops
• Add amlodipine if blood pressure remains elevated after 2-4 weeks of spironolactone therapy
• Amlodipine starting dose: 0.625-1.25 mg per cat orally every 24 hours, titrated to effect

Document all dose changes, response data, and adverse effects in the medical record. The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines provide general monitoring recommendations for endocrine disorders, supporting the use of structured follow-up protocols.

Step 7: Monitoring Protocol and Recheck Schedule

Establish a monitoring schedule based on disease severity and treatment response:

Initial Stabilization Phase (First 4 Weeks)

• Week 1: Blood pressure and electrolytes
• Week 2: Blood pressure and electrolytes
• Week 4: Blood pressure, electrolytes, and renal function

Long-Term Monitoring (After Stabilization)

• Every 3 months: Blood pressure, electrolytes, and renal function
• Every 6 months: Complete biochemistry panel and urinalysis
• Annually: Abdominal ultrasound to reassess adrenal glands

Unscheduled Rechecks

• Any recurrence of clinical signs (weakness, ventroflexion, blindness)
• Suspected adverse drug reactions
• Intercurrent illness that may affect electrolyte balance

Record all monitoring data in a standardized format to track trends over time.

Step 8: Escalation Criteria for Specialist Referral

Refer to a veterinary internal medicine specialist or veterinary teaching hospital in the following situations:

• Diagnostic uncertainty after initial workup (equivocal ARR, negative imaging with high suspicion)
• Complex surgical cases (large adrenal mass, suspected carcinoma, bilateral disease)
• Poor response to medical therapy (persistent hypertension or hypokalemia despite optimized treatment)
• Complications of therapy (severe hyperkalemia, renal deterioration, adverse drug reactions)
• Need for advanced imaging (CT, MRI) or specialized testing (adrenal vein sampling)

The American College of Veterinary Internal Medicine (ACVIM) provides resources for locating board-certified specialists.

Record System for Case Management

Maintain a dedicated record for each suspected or confirmed case. The following fields should be included:

Patient Information

• Signalment (age, breed, sex)
• Presenting complaint and duration
• Concurrent medications and medical conditions

Diagnostic Data

• Blood pressure measurements with date, time, and method
• Serum potassium and sodium concentrations with dates
• Aldosterone and renin activity results with ARR calculation
• Imaging reports with adrenal dimensions and characteristics

Treatment History

• Drug, dose, frequency, and start date for each medication
• Dose adjustments with rationale
• Adverse effects and interventions

Monitoring Data

• Blood pressure, electrolytes, and renal function at each recheck
• Clinical response assessment (resolution of signs, quality of life)
• Complications and outcomes

Surgical Data (if applicable)

• Preoperative stabilization details
• Surgical report including findings and complications
• Postoperative monitoring and recovery

These records support clinical decision-making, facilitate referral communication, and contribute to the evidence base for feline hyperaldosteronism management.

Common Failure Patterns in the Decision Framework

Failure to Screen At-Risk Populations Many clinicians do not routinely measure blood pressure in cats, leading to missed diagnoses. Hypertension is often asymptomatic until advanced, and hypokalemia may be intermittent. The 2020 review in The Veterinary Clinics of North America. Small Animal Practice emphasizes that primary hyperaldosteronism is underdiagnosed, suggesting that systematic screening in at-risk populations would improve detection rates.

Inadequate Sample Handling Improper collection or handling of samples for aldosterone and renin testing can yield false results. Delayed centrifugation, use of incorrect tubes, or improper storage can degrade these labile hormones. Strict adherence to laboratory protocols is essential.

Misinterpretation of Imaging Small adrenal nodules may be missed on ultrasound, and bilateral hyperplasia can be subtle. CT provides better sensitivity for detecting adrenal abnormalities. If clinical suspicion remains high despite negative imaging, referral to a specialist center for advanced imaging should be considered.

Incomplete Preoperative Stabilization Surgery on a cat with uncontrolled hypertension or severe hypokalemia carries increased anesthetic risk. Preoperative optimization of blood pressure and electrolytes is mandatory. The 2007 review in Clinical Techniques in Small Animal Practice discusses perioperative considerations for feline adrenal disorders.

Inadequate Long-Term Monitoring Cats on medical therapy require lifelong monitoring. Spironolactone can cause hyperkalemia, especially in cats with concurrent renal disease. Antihypertensive doses may need adjustment over time. Regular rechecks are necessary to maintain control and detect complications.

Limitations of the Decision Framework

The decision framework is a guide and does not replace clinical judgment. Individual patient factors, owner preferences, and resource availability may influence management decisions. The aldosterone:renin ratio is not 100% sensitive or specific, and confirmatory testing may be needed in equivocal cases. The 2010 review in The Veterinary Clinics of North America. Small Animal Practice discusses diagnostic challenges in feline primary hyperaldosteronism.

Spironolactone is not approved for use in cats by regulatory agencies in many countries, its use is extra-label. Clinicians should obtain informed consent and document the rationale for its use. The World Organisation for Animal Health provides general guidance on responsible therapeutic use, though specific feline endocrinology guidelines are not within its scope.

Welfare and Safety Context

Feline hyperaldosteronism is a serious condition that can cause significant morbidity if untreated. Hypertension can lead to acute blindness, retinal detachment, and neurologic signs. Hypokalemia can cause severe muscle weakness, cervical ventroflexion, and respiratory compromise. Early diagnosis and appropriate management improve outcomes and quality of life.

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines emphasize the importance of systematic evaluation in cats with compatible clinical signs. These guidelines support the use of standardized diagnostic protocols to improve detection rates for conditions such as hyperaldosteronism.

Clinicians should be aware of the welfare implications of delayed diagnosis. Cats with undiagnosed hyperaldosteronism may suffer from chronic hypertension and hypokalemia, leading to progressive renal damage, cardiac changes, and neurologic deficits. Prompt recognition and treatment are essential to prevent irreversible complications.

Practical Implementation Steps for the Decision Framework

1. Identify suspect cases using the risk stratification criteria
2. Perform initial laboratory workup including electrolytes and thyroid testing
3. Collect samples for aldosterone:renin ratio following proper handling protocols
4. Interpret ARR results using laboratory reference intervals
5. Perform adrenal imaging with ultrasound or CT
6. Select treatment based on lesion type and patient factors
7. Initiate medical therapy with spironolactone and antihypertensives as needed
8. Monitor response at scheduled intervals
9. Escalate to specialist when criteria are met
10. Maintain detailed records for each case

This framework provides a structured approach to managing feline hyperaldosteronism, from initial suspicion through long-term monitoring. By following these steps and documenting outcomes, clinicians can improve diagnostic accuracy, treatment success, and patient welfare.

Practical Decision Framework for Feline Hyperaldosteronism Management

A structured decision framework helps clinicians navigate the diagnostic and therapeutic steps for feline hyperaldosteronism with clarity and consistency. This section provides a stepwise approach to case management, from initial suspicion through long-term monitoring, with specific criteria for treatment selection and escalation. The framework is designed to be used alongside clinical judgment and is grounded in the diagnostic principles outlined in the 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines and the 2020 review in The Veterinary Clinics of North America. Small Animal Practice.

Step 1: Case Identification and Risk Stratification

The first decision point is identifying cats that warrant diagnostic evaluation for hyperaldosteronism. The following criteria should trigger a full workup:

• Systolic blood pressure consistently above 160 mmHg measured by Doppler or oscillometric methods following standard protocols
• Serum potassium concentration below 3.5 mEq/L on at least one occasion
• Compatible clinical signs including cervical ventroflexion, episodic weakness, acute blindness, or retinal detachment
• Unexplained polyuria and polydipsia with normal renal function

Cats meeting one or more of these criteria should be classified as high priority for diagnostic testing. Cats with hypertension alone, without hypokalemia, should still be considered for screening if other causes of hypertension (hyperthyroidism, chronic kidney disease, diabetes mellitus) have been excluded. The Merck Veterinary Manual provides general guidance on feline hypertension evaluation, noting that systolic blood pressure above 160 mmHg warrants investigation for underlying causes.

Step 2: Initial Laboratory Assessment and Sample Collection

Once a suspect case is identified, the following laboratory tests should be performed:

• Complete blood count
• Biochemistry panel including electrolytes, creatinine, blood urea nitrogen, and glucose
• Total thyroxine to rule out hyperthyroidism
• Urinalysis with specific gravity

If hypokalemia and hypertension are confirmed, proceed to collect samples for aldosterone and renin testing. Sample handling is critical for accurate results. Use the following protocol:

• Collect blood into chilled EDTA tubes
• Centrifuge within 30 minutes of collection
• Separate plasma and freeze immediately
• Ship on dry ice to a reference laboratory with validated feline assays
• Record collection time, handling details, and laboratory results in the medical record

The 2020 review in The Veterinary Clinics of North America. Small Animal Practice emphasizes that primary hyperaldosteronism is underdiagnosed, and proper sample handling is essential to avoid false negatives.

Step 3: Interpretation of Aldosterone:Renin Ratio

The aldosterone:renin ratio (ARR) is the recommended screening test. Interpretation requires understanding of the expected patterns:

• Primary hyperaldosteronism: Elevated aldosterone with suppressed renin, resulting in a high ARR
• Secondary hyperaldosteronism: Elevated aldosterone with elevated renin, resulting in a normal or low ARR
• Normal: Aldosterone and renin within reference ranges

Reference ranges vary by laboratory, and clinicians should use the reference intervals provided by their specific laboratory. If the ARR is equivocal or clinical suspicion remains high despite a normal ARR, consider confirmatory testing or referral to a veterinary internal medicine specialist. The 2010 review in The Veterinary Clinics of North America. Small Animal Practice provides historical context on diagnostic approaches for feline primary hyperaldosteronism.

Step 4: Adrenal Imaging and Lesion Characterization

Abdominal ultrasound is the initial imaging modality. Record the following findings:

• Adrenal gland dimensions (normal feline adrenal glands are approximately 10-15 mm in length)
• Presence of discrete nodules or masses
• Echogenicity and shape of the adrenal glands
• Evidence of invasion into surrounding tissues
• Presence of metastases in the liver, spleen, or regional lymph nodes

If a unilateral mass is identified, computed tomography (CT) is recommended for surgical planning. CT provides superior anatomic detail and can detect smaller lesions missed on ultrasound. The 2007 review in Clinical Techniques in Small Animal Practice discusses feline adrenal disorders and imaging characteristics, providing guidance on interpretation of adrenal imaging findings.

Step 5: Treatment Selection Based on Lesion Type

The treatment decision is based on the type of adrenal pathology identified:

Unilateral Aldosteronoma (Adenoma or Carcinoma)

• Surgical adrenalectomy is the treatment of choice if no metastases are present
• Preoperative stabilization is essential: control blood pressure with amlodipine and normalize potassium with supplementation
• Refer to a veterinary surgical specialist or teaching hospital for the procedure
• Postoperative monitoring includes blood pressure, electrolytes, and cortisol levels

Bilateral Adrenal Hyperplasia

• Medical management with spironolactone is indicated
• Antihypertensive therapy with amlodipine is often required concurrently
• Potassium supplementation may be needed initially but should be tapered as spironolactone takes effect
• Lifelong monitoring is necessary

Non-Surgical Candidate (Regardless of Lesion Type)

• Cats with metastatic disease, severe concurrent illness, or owner preference against surgery
• Medical management as above
• Regular monitoring for disease progression

The 2001 review in The Veterinary Clinics of North America. Small Animal Practice discusses surgical considerations for feline endocrine disorders, including perioperative management of adrenal disease.

Step 6: Medical Therapy Initiation and Dose Adjustment

For cats receiving spironolactone, use the following approach:

• Starting dose: 1-2 mg/kg orally every 12 hours
• Monitor electrolytes 1-2 weeks after initiation
• Adjust dose based on potassium response: increase if hypokalemia persists, decrease if hyperkalemia develops
• Add amlodipine if blood pressure remains elevated after 2-4 weeks of spironolactone therapy
• Amlodipine starting dose: 0.625-1.25 mg per cat orally every 24 hours, titrated to effect

Document all dose changes, response data, and adverse effects in the medical record. The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines provide general monitoring recommendations for endocrine disorders, supporting the use of structured follow-up protocols.

Step 7: Monitoring Protocol and Recheck Schedule

Establish a monitoring schedule based on disease severity and treatment response:

Initial Stabilization Phase (First 4 Weeks)

• Week 1: Blood pressure and electrolytes
• Week 2: Blood pressure and electrolytes
• Week 4: Blood pressure, electrolytes, and renal function

Long-Term Monitoring (After Stabilization)

• Every 3 months: Blood pressure, electrolytes, and renal function
• Every 6 months: Complete biochemistry panel and urinalysis
• Annually: Abdominal ultrasound to reassess adrenal glands

Unscheduled Rechecks

• Any recurrence of clinical signs (weakness, ventroflexion, blindness)
• Suspected adverse drug reactions
• Intercurrent illness that may affect electrolyte balance

Record all monitoring data in a standardized format to track trends over time.

Step 8: Escalation Criteria for Specialist Referral

Refer to a veterinary internal medicine specialist or veterinary teaching hospital in the following situations:

• Diagnostic uncertainty after initial workup (equivocal ARR, negative imaging with high suspicion)
• Complex surgical cases (large adrenal mass, suspected carcinoma, bilateral disease)
• Poor response to medical therapy (persistent hypertension or hypokalemia despite optimized treatment)
• Complications of therapy (severe hyperkalemia, renal deterioration, adverse drug reactions)
• Need for advanced imaging (CT, MRI) or specialized testing (adrenal vein sampling)

The American College of Veterinary Internal Medicine (ACVIM) provides resources for locating board-certified specialists.

Record System for Case Management

Maintain a dedicated record for each suspected or confirmed case. The following fields should be included:

Patient Information

• Signalment (age, breed, sex)
• Presenting complaint and duration
• Concurrent medications and medical conditions

Diagnostic Data

• Blood pressure measurements with date, time, and method
• Serum potassium and sodium concentrations with dates
• Aldosterone and renin activity results with ARR calculation
• Imaging reports with adrenal dimensions and characteristics

Treatment History

• Drug, dose, frequency, and start date for each medication
• Dose adjustments with rationale
• Adverse effects and interventions

Monitoring Data

• Blood pressure, electrolytes, and renal function at each recheck
• Clinical response assessment (resolution of signs, quality of life)
• Complications and outcomes

Surgical Data (if applicable)

• Preoperative stabilization details
• Surgical report including findings and complications
• Postoperative monitoring and recovery

These records support clinical decision-making, facilitate referral communication, and contribute to the evidence base for feline hyperaldosteronism management.

Common Failure Patterns in the Decision Framework

Failure to Screen At-Risk Populations Many clinicians do not routinely measure blood pressure in cats, leading to missed diagnoses. Hypertension is often asymptomatic until advanced, and hypokalemia may be intermittent. The 2020 review in The Veterinary Clinics of North America. Small Animal Practice emphasizes that primary hyperaldosteronism is underdiagnosed, suggesting that systematic screening in at-risk populations would improve detection rates.

Inadequate Sample Handling Improper collection or handling of samples for aldosterone and renin testing can yield false results. Delayed centrifugation, use of incorrect tubes, or improper storage can degrade these labile hormones. Strict adherence to laboratory protocols is essential.

Misinterpretation of Imaging Small adrenal nodules may be missed on ultrasound, and bilateral hyperplasia can be subtle. CT provides better sensitivity for detecting adrenal abnormalities. If clinical suspicion remains high despite negative imaging, referral to a specialist center for advanced imaging should be considered.

Incomplete Preoperative Stabilization Surgery on a cat with uncontrolled hypertension or severe hypokalemia carries increased anesthetic risk. Preoperative optimization of blood pressure and electrolytes is mandatory. The 2007 review in Clinical Techniques in Small Animal Practice discusses perioperative considerations for feline adrenal disorders.

Inadequate Long-Term Monitoring Cats on medical therapy require lifelong monitoring. Spironolactone can cause hyperkalemia, especially in cats with concurrent renal disease. Antihypertensive doses may need adjustment over time. Regular rechecks are necessary to maintain control and detect complications.

Limitations of the Decision Framework

The decision framework is a guide and does not replace clinical judgment. Individual patient factors, owner preferences, and resource availability may influence management decisions. The aldosterone:renin ratio is not 100% sensitive or specific, and confirmatory testing may be needed in equivocal cases. The 2010 review in The Veterinary Clinics of North America. Small Animal Practice discusses diagnostic challenges in feline primary hyperaldosteronism.

Spironolactone is not approved for use in cats by regulatory agencies in many countries, its use is extra-label. Clinicians should obtain informed consent and document the rationale for its use. The World Organisation for Animal Health provides general guidance on responsible therapeutic use, though specific feline endocrinology guidelines are not within its scope.

Welfare and Safety Context

Feline hyperaldosteronism is a serious condition that can cause significant morbidity if untreated. Hypertension can lead to acute blindness, retinal detachment, and neurologic signs. Hypokalemia can cause severe muscle weakness, cervical ventroflexion, and respiratory compromise. Early diagnosis and appropriate management improve outcomes and quality of life.

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines emphasize the importance of systematic evaluation in cats with compatible clinical signs. These guidelines support the use of standardized diagnostic protocols to improve detection rates for conditions such as hyperaldosteronism.

Clinicians should be aware of the welfare implications of delayed diagnosis. Cats with undiagnosed hyperaldosteronism may suffer from chronic hypertension and hypokalemia, leading to progressive renal damage, cardiac changes, and neurologic deficits. Prompt recognition and treatment are essential to prevent irreversible complications.

Practical Implementation Steps for the Decision Framework

1. Identify suspect cases using the risk stratification criteria
2. Perform initial laboratory workup including electrolytes and thyroid testing
3. Collect samples for aldosterone:renin ratio following proper handling protocols
4. Interpret ARR results using laboratory reference intervals
5. Perform adrenal imaging with ultrasound or CT
6. Select treatment based on lesion type and patient factors
7. Initiate medical therapy with spironolactone and antihypertensives as needed
8. Monitor response at scheduled intervals
9. Escalate to specialist when criteria are met
10. Maintain detailed records for each case

This framework provides a structured approach to managing feline hyperaldosteronism, from initial suspicion through long-term monitoring. By following these steps and documenting outcomes, clinicians can improve diagnostic accuracy, treatment success, and patient welfare.

Frequently Asked Questions

What is the difference between primary and secondary hyperaldosteronism in cats?

Primary hyperaldosteronism results from autonomous aldosterone secretion by the adrenal gland, independent of the renin-angiotensin system. Secondary hyperaldosteronism is caused by increased renin activity due to conditions such as renal disease, heart failure, or liver disease. The aldosterone:renin ratio helps distinguish these: it is elevated in primary disease and normal or low in secondary disease.

How is feline hyperaldosteronism diagnosed?

Diagnosis involves measuring plasma aldosterone concentration and plasma renin activity to calculate the aldosterone:renin ratio. A high ratio with suppressed renin indicates primary hyperaldosteronism. Adrenal imaging with ultrasound or CT identifies the underlying adrenal pathology. The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines provide a diagnostic framework.

What are the treatment options for feline hyperaldosteronism?

Treatment depends on the underlying cause. Unilateral aldosteronoma is treated with surgical adrenalectomy. Bilateral hyperplasia or non-surgical candidates are managed medically with spironolactone, a mineralocorticoid receptor antagonist, along with antihypertensives such as amlodipine. Potassium supplementation may be needed initially.

Can feline hyperaldosteronism be cured?

Unilateral aldosteronoma can be cured by surgical removal of the affected adrenal gland, with resolution of hypertension and hypokalemia in many cases. Bilateral hyperplasia is not curable but can be managed long-term with medical therapy. Adrenal carcinoma carries a guarded prognosis due to risk of metastasis.

What is the prognosis for cats with hyperaldosteronism?

Prognosis depends on the underlying cause and response to treatment. Cats with unilateral adenoma that undergo successful adrenalectomy often have a good prognosis. Cats with bilateral hyperplasia or carcinoma require lifelong management and have a more guarded outlook. Regular monitoring is essential for all cases.

How often should blood pressure be monitored in treated cats?

Blood pressure should be measured 1-2 weeks after initiating or adjusting antihypertensive therapy, then every 3-6 months once stable. More frequent monitoring is indicated if blood pressure is poorly controlled or if clinical signs recur. The goal is systolic blood pressure below 160 mmHg.

What are the side effects of spironolactone in cats?

Spironolactone can cause gastrointestinal upset, hyperkalemia, and rarely, antiandrogenic effects. Hyperkalemia is more common in cats with concurrent renal disease. Electrolytes should be monitored 1-2 weeks after starting therapy and periodically thereafter. Dose adjustments may be needed.

When should I refer a cat with suspected hyperaldosteronism?

Referral to a veterinary internal medicine specialist is indicated for diagnostic uncertainty, complex surgical cases, poor response to medical therapy, or complications of treatment. Advanced imaging or specialized testing may require referral to a veterinary teaching hospital or specialty center.

Related Veterinary Guides

• Cat
• Clinical Biochemistry Urinalysis
• Hypertrophic Cardiomyopathy In Cats
• Prescription Medicine For Cats
• Sneezing Cat Remedy

References and Further Reading

• www.merckvetmanual.com
• catvets.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines.. Journal of the American Animal Hospital Association, 2023.
• Primary Hyperaldosteronism in Cats: An Underdiagnosed Disorder.. The Veterinary clinics of North America. Small animal practice, 2020.
• Feline primary hyperaldosteronism.. The Veterinary clinics of North America. Small animal practice, 2010.
• Feline adrenal disorders.. Clinical techniques in small animal practice, 2007.
• Feline endocrinopathies.. The Veterinary clinics of North America. Small animal practice, 2005.
• Feline endocrinology update.. The Veterinary clinics of North America. Small animal practice, 2001.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.